Anti-Golga3 antibody in the study ”Novel players and large-scale protein dynamics of BCR activation revealed by APEX2 proximity labelling of lipid rafts”


March, 2021 (Institute of Biomedicine and MediCity Research Laboratories, University of Turku, Finland)

Successful B cell activation, critical for high-affinity antibody production, is controlled by the B cell antigen receptor (BCR).

By using our anti-Golga3 antibody (HPA040044), in immunofluorescence, this study validates Golga3 (together with other targets) as a novel protein responding to BCR activation.


The data provides a new understanding of the behavior of proteins known to be involved in the proximal antigen receptor signaling, and the simultaneously triggered processes, such as actin cytoskeleton remodeling and endocytosis.

Read more:

Antibody page: